UB391
TargetsHer2/Her2
IndicationsBreast cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer
ClinicalCN - III
TherapeuticsOncology
ModalitiesADC
Exclusive Summary
- • Trageting ECD2/4, promising data readout at ASCO 2025 (HR+BC) and WCLC 2025 (NSCLC), with potential better performance at HER low+indication and better safety profile( RP2D dose ORR 58.33% DCR 86.11%) . Rare Interstitial lung diseases were reported.
- • Favorable competitive landscape for Bioparotopic Her2 ADC.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →